Update on Assessment of Estimated Glomerular Filtration Rate in Patients with Cirrhosis
DOI:
https://doi.org/10.70749/ijbr.v3i5.1511Keywords:
Cirrhosis, eGFR, Creatinine, Cystatin CAbstract
Background: cirrhosis causes muscle loss and changes in creatinine levels, it is difficult to assess renal function in these patients. Often, creatinine-based processes calculate GFR too high which causes renal diseases to be diagnosed late and the illness to be undertreated. Objectives: To study which eGFR equation works best in cirrhotic patients and can most reliably be used in assessing and detecting early kidney impairment. Study Design: A Cross-Sectional Study. Place and Duration of study: From May 2024 to December 2024 Nephrology & Gastroenterology Department, Sandeman Provincial Hospital / Bolan Medical College / Hospital, Quetta. Methods: This cross-sectional study was performed at Nephrology & Gastroenterology Department, SPH/BMCH, Quetta. One hundred and twenty-five people with cirrhosis participated in the study. Serum creatinine, cystatin C and true GFR by radionuclide scanning were all measured. Creatinine and cystatin C, MDRD and Cockcroft-Gault formulas were used for estimating GFR. The statistical comparisons were made using version 24 of SPSS. Results: The average age among the 125 cirrhotic patients was 56.8, with a variance of 10.2 years. More men (61.6%) than women were part of the study. Compared to measured GFR, the CKD-EPI creatinine-cystatin C formula showed the best correlation (r = 0.82, p < 0.001). Both the MDRD and Cockcroft-Gault equations were found to overestimate GFR by about 11 and 15 mL per minute per square meter (p<0.01). Patients in Child-Pugh class C experienced the greatest difference between the GFR predicted and the GFR measured. Calculations that use Cystatin C gave the best outcomes in patients with more advanced liver disease. Conclusion: For people with cirrhosis, the common eGFR formulas using creatinine may give a misleading assessment of renal function. For patients with kidney disease, especially when creatinine becomes less accurate, use of CKD-EPI that includes cystatin C is the best option.
Downloads
References
Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, et al. Working party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut. 2011;60(5):702–709.
https://doi.org/10.1136/gut.2010.236133
Fede G, Privitera G, Tomaselli T, Spadaro L, Rabuazzo AM, Cammà C, et al. Clinical impact of renal dysfunction on survival of patients with cirrhosis. World J Hepatol. 2012;4(9):302–309.
https://doi.org/10.1016/s0168-8278(11)60183-9
Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis. 2003;41(2):269–278.
https://doi.org/10.1053/ajkd.2003.50035
Mindikoglu AL, Regev A, Magder LS. Evaluation of creatinine-based estimates of glomerular filtration rate in patients with liver disease. Clin Gastroenterol Hepatol. 2008;6(5):555–561.
https://doi.org/10.1097/tp.0b013e3181605fda
Francoz C, Nadim MK, Baron A, Prie D, Belghiti J, Valla D, et al. Glomerular filtration rate equations for liver-kidney transplantation in patients with cirrhosis: validation of current recommendations. Hepatology. 2014;59(4):1514–1521.
https://doi.org/10.1002/hep.26704
Pöge U, Gerhardt T, Stoffel-Wagner B, Palmedo H, Klehr HU, Sauerbruch T, et al. Cystatin C-based calculation of glomerular filtration rate in comparison with other methods in patients with impaired liver function. Clin Chem. 2006;52(10):1711–1716.
https://doi.org/10.1038/sj.ki.5001502
Belcher JM, Garcia-Tsao G, Sanyal AJ, Bhogal H, Lim JK, Ansari N, et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology. 2013;57(2):753–762.
https://doi.org/10.1002/hep.25735
Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med. 2006;354(23):2473–2483.
https://doi.org/10.1056/nejmra054415
Fagundes C, Barreto R, Guevara M, Wang Y, Jensen J, Lescure FX, et al. A modified MELD score including serum cystatin C improves mortality prediction in patients with cirrhosis. J Hepatol. 2013;59(2):365–371.
Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310–1318.
https://doi.org/10.1136/gut.2006.107789
MacAulay TE, McCullough PA. Cystatin C: measurement procedures and clinical relevance. Clin Biochem Rev. 2007;28(3):115–118.
Adachi M, Brenner BM. Determinants of glomerular filtration rate in cirrhosis. Am J Kidney Dis. 1990;16(3):236–243.
Ariza X, Graupera I, Barreto R, et al. Cystatin C-based equations improve the detection of renal dysfunction in patients with cirrhosis. J Hepatol. 2013;59(3):399–407.
Eason JD, Gonwa TA, Davis CL, Sung RS, Gerber D, Bloom RD. Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK). Am J Transplant. 2008;8(11):2243–2251.
https://doi.org/10.1111/j.1600-6143.2008.02416.x
Lumlertgul N, Davenport A. Accuracy of eGFR in assessing kidney function in liver cirrhosis. Clin Kidney J. 2018;11(4):494–501.
Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361(13):1279–1290.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
